Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DSSM: Distributed Streaming Data Sharing Manager.
Fukuda H, Gunji R, Hasegawa T, Leger P, Figueroa I. Fukuda H, et al. Among authors: gunji r. Sensors (Basel). 2021 Feb 14;21(4):1344. doi: 10.3390/s21041344. Sensors (Basel). 2021. PMID: 33672793 Free PMC article.
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Utsunomiya K, Koshida R, Kakiuchi S, Senda M, Fujii S, Kurihara Y, Gunji R, Kaku K. Utsunomiya K, et al. Among authors: gunji r. J Diabetes Investig. 2021 Feb;12(2):184-199. doi: 10.1111/jdi.13333. Epub 2020 Aug 25. J Diabetes Investig. 2021. PMID: 32597517 Free PMC article.
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Utsunomiya K, Kakiuchi S, Senda M, Fujii S, Kurihara Y, Gunji R, Koshida R, Kameda H, Tamura M, Kaku K. Utsunomiya K, et al. Among authors: gunji r. J Diabetes Investig. 2020 Jul;11(4):906-916. doi: 10.1111/jdi.13233. Epub 2020 Mar 15. J Diabetes Investig. 2020. PMID: 32034997 Free PMC article.
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y, Gunji R, Fujii S, Kaku K. Utsunomiya K, et al. Among authors: gunji r. J Diabetes Investig. 2020 Jan;11(1):132-141. doi: 10.1111/jdi.13097. Epub 2019 Jul 8. J Diabetes Investig. 2020. PMID: 31197929 Free PMC article.
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, Gunji R, Kaku K. Terauchi Y, et al. Among authors: gunji r. J Diabetes Investig. 2019 Nov;10(6):1518-1526. doi: 10.1111/jdi.13066. Epub 2019 May 28. J Diabetes Investig. 2019. PMID: 31033218 Free PMC article. Clinical Trial.
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y, Gunji R, Fujii S, Fujiwara H, Kaku K. Utsunomiya K, et al. Among authors: gunji r. J Diabetes Investig. 2019 Sep;10(5):1272-1283. doi: 10.1111/jdi.13017. Epub 2019 Mar 6. J Diabetes Investig. 2019. PMID: 30702214 Free PMC article.
18 results